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S U M M A R Y
Background: From July to October 2008, 34 Acinetobacter baumannii isolates were involved in an outbreak
at the Clinical Hospital Center, Zagreb. The aim of this study was to characterize the mechanisms of
carbapenem resistance in our A. baumannii isolates and determine their epidemiology.
Methods: Antibiotic susceptibilities were determined by broth microdilution. PCR was used to detect the
presence of carbapenemases. Genotyping of the isolates was performed by random ampliﬁcation of
polymorphic DNA (RAPD), pulsed-ﬁeld gel electrophoresis (PFGE), and repetitive sequence-based PCR
(rep-PCR).
Results: Thirty-three carbapenem-resistant isolates were positive for the acquired blaOXA-72 and one
unrelated isolate was positive for blaOXA-58. The blaOXA-72-positive isolates were shown to be clonally
related by RAPD, rep-PCR, and PFGE.
Conclusions: On the basis of susceptibility testing, b-lactamase characterization, and genotyping of the
isolates we can conclude that clonal spread of endemic isolates was responsible for the high frequency of
OXA-72-positive multidrug-resistant A. baumannii in this setting. Most of the isolates originated from
the intensive care unit indicating local dissemination within the hospital and pointing to the potential
source of isolates.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Carbapenems have a potent activity against Acinetobacter and
are often used as a last resort for the treatment of infections due to
multi-resistant Acinetobacter baumannii isolates.1 However, A.
baumannii may develop resistance to carbapenems through
various combined mechanisms, including decreased permeability,
altered penicillin binding proteins (PBPs) and, rarely, efﬂux pump
overexpression.2 The most frequent mechanism of resistance is
through the production of class D oxacillinases (OXA). The intrinsic
blaOXA-51-like and the acquired blaOXA genes (23-like, 40-like, 58-
like, and 143) are often associated with insertion elements that are
thought to upregulate expression.3 Less common are class B IMP-
and VIM-type metallo-b-lactamases (MBLs).4 Recently an increase§ These results were presented in part at the European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID) 2010, Vienna, Austria.
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doi:10.1016/j.ijid.2011.05.016in the prevalence of carbapenem-resistant A. baumannii isolates
has been observed at the Clinical Hospital Center Zagreb. The aim
of this study was to characterize the mechanisms of carbapenem
resistance in our A. baumannii isolates and their molecular
epidemiology.
2. Materials and methods
2.1. Bacterial isolates
Thirty-four non-duplicate A. baumannii isolates (one isolate per
patient) with reduced susceptibility to imipenem and meropenem
by disk diffusion (zone diameter 16 mm) were collected between
July and October 2008 from various clinical specimens and hospital
units (Table 1).
2.2. Susceptibility testing
The antimicrobial susceptibility to a wide range of antibiotics
was determined by broth microdilution in accordance with theses. Published by Elsevier Ltd. All rights reserved.
Table 1
Minimum inhibitory concentrations (mg/ml) of various antibiotics and genotyping of oxacillinase-producing Acinetobacter baumannii strains
Strain Specimen Hospital ward Date of
isolationa
OXA-51-like Acquired
oxacillinase
FEP TZP SAM IPM MEM GEN AMK CIP COL
1b Gastric ﬂuid ICU 11/08/08 OXA-68 OXA-58 16 256 64 16 16 32 8 32 2
2 Urine ICU 10/07/08 OXA-66/76 OXA-72 16 256 64 64 64 32 32 8 2
3 Gastric ﬂuid ICU 10/07/08 OXA-66/76 OXA-72 16 256 64 64 256 128 8 2 2
4 Urine Ophthalmology 14/07/08 OXA-66/76 OXA-72 16 >256 128 256 >256 32 8 4 2
5 Tr. aspirate ICU 16/07/08 OXA-66/76 OXA-72 16 256 16 128 128 64 8 8 2
6 Tr. aspirate ICU 16/07/08 OXA-66/76 OXA-72 16 >256 >128 256 >256 512 8 8 2
7 CSF ICU 17/07/08 OXA-66/76 OXA-72 32 >256 128 256 >256 256 8 8 2
8 Tr. aspirate ICU 21/07/08 OXA-66/76 OXA-72 16 256 128 128 >256 256 8 8 2
9 Tr. aspirate ICU 21/07/08 OXA-66/76 OXA-72 32 >256 64 256 >256 64 16 8 2
10 Drain Surgery 27/07/08 OXA-66/76 OXA-72 16 >256 64 128 >256 64 8 8 2
11b Tr. aspirate ICU 28/07/08 OXA-66/76 OXA-72 16 >256 128 256 >256 32 8 8 2
12 Tr. aspirate ICU 31/07/08 OXA-66/76 OXA-72 32 >256 >128 256 >256 64 16 8 2
13b Canulla swab Ped ICU 01/08/08 OXA-66/76 OXA-72 16 >256 >128 128 >256 64 16 8 2
14 Tr. aspirate Ped ICU 01/08/08 OXA-66/76 OXA-72 16 >256 128 128 >256 64 16 8 2
15 Tr. aspirate Ped ICU 14/08/08 OXA-66/76 OXA-72 16 >256 128 128 >256 64 32 32 2
16b Tr. aspirate Ped surgery 14/08/08 OXA-66/76 OXA-72 32 >256 64 128 >256 64 8 64 2
17 Tr. aspirate ICU 21/08/08 OXA-66/76 OXA-72 16 >256 128 128 >256 64 4 8 2
18 Wound swab Hematology 21/08/08 OXA-66/76 OXA-72 16 256 128 128 256 64 8 8 2
19 Tr. aspirate ICU 28/08/08 OXA-66/76 OXA-72 16 >256 >128 128 >256 64 8 8 2
20 Gastric ﬂuid ICU 22/09/08 OXA-66/76 OXA-72 32 >256 128 128 32 64 32 16 1
21 Drain tip ICU 23/09/08 OXA-66/76 OXA-72 16 >256 64 128 >128 32 16 4 1
22 Tr. aspirate ICU 29/09/08 OXA-66/76 OXA-72 32 >256 128 256 >256 128 32 8 2
23 Tr. aspirate ICU 29/09/08 OXA-66/76 OXA-72 32 >256 128 256 >256 32 16 8 1
24 Tr. aspirate ICU 02/10/08 OXA-66/76 OXA-72 32 >256 128 >256 >256 32 16 8 1
25b Tr. aspirate ICU 02/10/08 OXA-66/76 OXA-72 16 >256 64 256 >256 64 8 8 2
26b Blood culture ICU 03/10/08 OXA-66/76 OXA-72 32 >256 128 256 >256 64 8 8 2
27 Gastric ﬂuid ICU 06/10/08 OXA-66/76 OXA-72 32 >256 64 128 32 32 64 8 2
28 Tr. aspirate ICU 06/10/08 OXA-66/76 OXA-72 64 >256 >128 256 >256 64 16 4 1
29 Tr. aspirate ICU 09/10/08 OXA-66/76 OXA-72 32 >256 128 256 >256 32 16 4 2
30b Gastric ﬂuid ICU 13/10/08 OXA-66/76 OXA-72 64 >256 128 >256 >256 64 16 8 2
31 Tr. aspirate ICU 15/10/08 OXA-66/76 OXA-72 64 >256 128 >256 >256 64 16 8 1
32 Abdominal swab ICU 20/10/08 OXA-66/76 OXA-72 16 256 16 64 256 256 8 8 2
33 Tr. aspirate ICU 22/09/08 OXA-66/76 OXA-72 64 >256 64 >256 >256 32 8 4 2
34b Tr. aspirate ICU 27/10/08 OXA-66/76 OXA-72 32 >256 256 >256 32 16 8 1
FEP, cefepime; TZP, piperacillin/tazobactam; SAM, sulbactam/ampicillin; IPM, imipenem; MEM, meropenem; GEN, gentamicin; AMK, amikacin; CIP, ciproﬂoxacin; COL,
colistin; ICU, neurosurgical intensive care unit; Ped ICU, pediatric intensive care unit; Tr. aspirate, tracheal aspirate; CSF, cerebrospinal ﬂuid.
a Day/month/year.
b Isolates on which rep-PCR was performed.
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Minimum inhibitory concentrations (MICs) of imipenem and
meropenem were also determined in the presence of sodium
chloride (200 mM) to inhibit OXA-58 b-lactamase and cloxacillin
(200 mg/l) to inhibit chromosomal AmpC b-lactamase.6 Pseudomo-
nas aeruginosa ATCC 27853 was used as the quality control strain.
2.3. Detection of metallo-b-lactamases
Etest MBL strips were used for the detection of metallo-
carbapenemases following the manufacturer’s instructions (AB
Biodisk, Solna, Sweden). Furthermore, the isolates were tested by
synergy test using imipenem and ethylenediaminetetraacetic acid
(EDTA)-containing disks to screen for metallo-b-lactamase pro-
duction.7
2.4. Characterization of b-lactamases
PCR was used to detect the presence of the genes encoding
metallo-b-lactamases, OXA-encoding genes, and blaTEM genes as
previously described.8–10 The genetic context of blaOXA-40-like and
blaOXA-58-like genes was determined by PCR mapping using ISAbaI
and ISAbaIII primers.11,12 Partial sequences of selected blaOXA-51-
like, blaOXA-40-like, and blaOXA-58-like genes were determined.
To determine if acquired oxacillinase genes were plasmid-
encoded, plasmid DNA was extracted using the QIAprep Spin
Miniprep Kit (Qiagen, Hilden, Germany) and transferred to A.
baumannii ATCC 19606 recipient isolate by electroporation.Transformants were selected on 100 mg/ml ticarcillin. In addition,
plasmid DNA was used as template for PCR for the detection of
blaOXA-40 and blaOXA-58 genes.
2.5. Genotyping of the isolates
All A. baumannii isolates were initially genotyped by random
ampliﬁcation of polymorphic DNA (RAPD) using M13 primer.13
Sequence groups (1–3) corresponding to EU clones I–III were
determined by multiplex PCR as described previously.14 Represen-
tative isolates were further investigated by repetitive sequence-
based PCR (rep-PCR) (DiversiLab System; bioMe´rieux, Nurtingen,
Germany) following the manufacturer’s instructions. Isolates that
clustered above 95% were considered related.15 Pulsed-ﬁeld gel
electrophoresis (PFGE) genotyping of XbaI-digested genomic DNA
was performed with a CHEF-DRIII system (Bio-Rad, Zagreb,
Croatia),16 the images were processed using Gel-Compar software,
and a dendrogram was computed after band intensity correlation
using global alignment with 1.5% optimization and UPGMA
(unweighted pair group method with arithmetic mean) cluster-
ing.17,18
3. Results
3.1. Antimicrobial susceptibility
MIC data are summarized in Table 1. All isolates were uniformly
resistant to ceftazidime, cefotaxime, ceftriaxone, piperacillin/
Figure 1. rep-PCR analysis: dendrogram and computer-generated image of rep-PCR
banding patterns showing representatives of the OXA-72 isolates and the OXA-58
isolate.
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imipenem. All isolates remained susceptible to colistin. Addition of
sodium chloride lowered the carbapenem MICs of the OXA-58 b-
lactamase-producing strain by two dilutions. Addition of cloxacil-
lin did not have any effect on MICs of imipenem or meropenem.
3.2. Characterization of b-lactamases
Thirty-three isolates were positive for the gene encoding OXA-
40-like b-lactamase and one OXA-58-like. ISAbaIII was found
upstream of the blaOXA-58-like gene and ISAbaI was associated with
the blaOXA-40-like genes. ISAbaI was not associated with blaOXA-51-
like. Only OXA-58-like b-lactamase was inhibited by sodium
chloride, lowering the imipenem MIC from 16 mg/l to 4 mg/l. No
MBLs were found. All isolates were positive for blaTEM. Sequencing
of the acquired OXA genes revealed blaOXA-72 and blaOXA-58 (Table
1). Electroporation experiments using plasmid extracts from
blaOXA-72- and blaOXA-58-positive isolates were unsuccessful in
transferring carbapenem resistance to electrocompetent A. bau-
mannii ATCC 19606. Plasmid bands were not visible after
electrophoresis of plasmid DNA and these plasmid preparations
were negative for blaOXA-72. Partial sequencing of the blaOXA-51-like
genes revealed that the blaOXA-72 isolates possessed blaOXA-66/76.
These genes differ at nucleotide 808, which was not covered by the
sequencing reaction. The blaOXA-58 isolate possessed blaOXA-68
(Table 1).
3.3. Genotyping of the isolates
The OXA-72 producers belonged to EU clone 2, which is in
agreement with possession of blaOXA-66/76 (sequence group I). The
OXA-58 strain did not cluster with any of the European clones.
RAPD analysis grouped the OXA-72 isolates together, and these
isolates showed identical banding patterns in rep-PCR (Figure 1).
The OXA-58 isolate was distinct. PFGE conﬁrmed the clonality of
the predominant A. baumannii blaOXA-72-positive isolates.
4. Discussion
Previously in Croatia, carbapenem resistance was associated
with upregulation of the blaOXA-51 gene by ISAbaI.
19 This study
found OXA-72, a member of the OXA-40 subclass, to be the most
prevalent carbapenem resistance determinant among our
A. baumannii isolates, and this represents the ﬁrst report ofOXA-72 in Croatia. Outbreaks of OXA-40-like are generally rare
except in Spain,20 as they are the least prevalent of OXAs and when
tested have been found more often in EU complex II.21–23 Our
isolates emerged in the summer of 2008. In January 2009, OXA-72-
producing A. baumannii isolates were reported from University
Hospital Split in Croatia. In contrast to our isolates, these isolates
were shown to possess integron-associated metallo-b-lactamase
in addition to OXA-72.
Clustering of A. baumannii isolates suggests either patient-to-
patient transmission or a common source of acquisition (e.g.,
contaminated equipment for mechanical ventilation). The wide
dissemination of EU clone II OXA-72 isolates has probably resulted
from its selective advantage in the antibiotic-rich hospital
environment and could further be facilitated by the lack of
effective measures to prevent hospital transmission. Other
European studies have already demonstrated the spread of EU
clone II isolates and the association of carbapenem resistance with
these isolates.21–23 OXA-72 b-lactamase with similar properties
has previously been reported in France,24 South Korea,25 Taiwan,26
China,27 and Brazil.28 In contrast to our results, they proved the
plasmid location of blaOXA-72 gene.
The isolates displayed high MICs for carbapenems, which could
also be attributed to other resistance mechanisms, such as porin
loss or upregulated efﬂux pumps,2,3 but clariﬁcation of these
additional resistance mechanisms was beyond the scope of this
study. Resistance to ampicillin/sulbactam is worrying and was
most likely due to the production of TEM b-lactamases.22 Colistin
became the antibiotic of choice for the treatment of infections
caused by our A. baumannii isolates, as this was the only
antimicrobial to have activity. However, the risk of nephrotoxicity
is of clinical concern. Tigecycline has been shown to be effective in
vitro and in vivo against multidrug-resistant A. baumannii,29 but is
not yet licensed in Croatia. The combination of tigecycline, colistin,
and meropenem has been shown to yield a favorable clinical
outcome against multi-resistant A. baumannii.30
In conclusion, this study highlights the propensity of clonal
spread of multidrug-resistant A. baumannii, in particular carbape-
nem-resistant isolates. Furthermore, the factors responsible for
dissemination of such isolates need to be identiﬁed, controlled, and
prevented to avoid major outbreaks.
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